Clinical trials to prevent Alzheimer's Disease in Down Syndrome

标题：NIH纳入ACTC-DS -带来Tau PET成像和血液的进展- 试验就绪队列-唐氏综合征（TRC-DS）的磷酸化tau生物标志物 摘要 有了这个补充，我们要求资金来实施多个新的测定， CSF和血液样本以及在研究中对一半参与者增加Tau PET成像， 阿尔茨海默氏症临床试验联盟-唐氏综合征（ACTC-DS）试验就绪队列- 唐氏综合征（TRC-DS）项目。Tau PET是了解AD的关键生物标志物 在DS和散发性人群中的病理学，似乎与 认知能力下降此外，最近的研究结果表明，Pospho-Tau-217（Ptau 217）可能 可能代表最准确的基于CSF和血液的AD生物标志物，因此将是 对DS人群的研究至关重要。

TITLE: NIH INCLUDE ACTC-DS – Bringing Advances in Tau PET imaging and blood- based biomarkers of Phospho-tau to the Trial-Ready Cohort – Down Syndrome (TRC-DS) ABSTRACT With this supplement, we request funding to implement multiple new assays to be performed on CSF and blood samples as well as the addition of Tau PET imaging on half of the participants in the Alzheimer's Clinical Trial Consortium – Down Syndrome (ACTC-DS) Trial Ready Cohort – Down syndrome (TRC-DS) Project. Tau PET is a critical biomarker in understanding AD pathology in DS and as in the sporadic population, seems to correlate more closely with cognitive decline. Moreover, recent findings indicate that Pospho-Tau-217 (Ptau217) may represent perhaps the most accurate CSF- and blood-based biomarker of AD and will thus be critically important to study in the DS population.